Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01)
NCT 05735080 Brief Summary Incyclix Bio (Incyclix) is developing INX-315 as an…
Read more arrow_forwardNCT 05735080 Brief Summary Incyclix Bio (Incyclix) is developing INX-315 as an…
Read more arrow_forwardNCT 06092580 Brief Summary The aims of this clinical trial are (1)…
Read more arrow_forwardNCT 03212404 Brief Summary CK-301 (cosibelimab) is a fully human monoclonal antibody…
Read more arrow_forwardNCT 05544552 Brief Summary The purpose of this study is to…
Read more arrow_forwardNCT 05267626 Brief Summary This is a first in human, open-label, multi-center…
Read more arrow_forwardNCT 04644068 Brief Summary This research is designed to determine if experimental…
Read more arrow_forwardNCT 02628067 Brief Summary In this study, participants with multiple types of…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this study…
Read more arrow_forwardNCT 06003621 Brief Summary This phase II study will explore the effect…
Read more arrow_forwardNCT 05356741 Brief Summary This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation…
Read more arrow_forward